9:47 am today
New Zealand's largest drug maker AFT Pharmaceuticals has reported strong full year sales growth and net profit, giving the company reason to lift its 2027 revenue target to more than $300 million.
Company chair David Flacks said the strength of its core Australasian business and increasing geographic and product diversification supported the strong result with double digit growth in all its regions.
Key numbers for the 12 months ended March compared with a year ago:
Net profit $14.7m v $12m up 23%
